Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors in East Asians with Type 2 Diabetes: A Systematic Review and Meta-Analysis
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors in East Asians with Type 2 Diabetes: A Systematic Review and Meta-Analysis
Authors
Keywords
East Asians, Sodium-glucose co-transporter 2 inhibitors, Type 2 diabetes mellitus
Journal
Diabetes Therapy
Volume 10, Issue 5, Pages 1921-1934
Publisher
Springer Science and Business Media LLC
Online
2019-08-02
DOI
10.1007/s13300-019-0674-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- An update on the safety of SGLT2 inhibitors
- (2019) André J Scheen Expert Opinion On Drug Safety
- SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials
- (2018) Robert Puckrin et al. ACTA DIABETOLOGICA
- Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial
- (2018) Ryuzo Kawamori et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial
- (2018) Kyung-Ah Han et al. DIABETES OBESITY & METABOLISM
- Glycaemic responses in Asian and non-Asian people with type 2 diabetes initiating insulin glargine 100 units/mL: A patient-level pooled analysis of 16 randomised controlled trials
- (2018) Juliana C.N. Chan et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Dapagliflozin improves blood glucose in diabetes on triple oral hypoglycemic agents having inadequate glucose control
- (2018) Hyun Jeong Jeon et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: A randomized controlled trial
- (2018) Wenying Yang et al. Journal of Diabetes
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Management of Type 2 Diabetes in 2017
- (2017) Jane E. B. Reusch et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin
- (2017) Hiroshi Nomoto et al. Diabetology & Metabolic Syndrome
- Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis
- (2017) Jiali Liu et al. Scientific Reports
- Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus
- (2016) Nobuya Inagaki et al. Cardiovascular Diabetology
- Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study
- (2016) Hisamitsu Ishihara et al. DIABETES OBESITY & METABOLISM
- Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives
- (2016) Yutaka Seino et al. Journal of Diabetes Investigation
- Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period
- (2016) Eiichi Araki et al. Journal of Diabetes Investigation
- SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis
- (2016) Deepson S Shyangdan et al. BMJ Open
- Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial
- (2016) Wenying Yang et al. Journal of Diabetes
- The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus
- (2015) Volker Vallon Annual Review of Medicine
- β Cell Dysfunction Versus Insulin Resistance in the Pathogenesis of Type 2 Diabetes in East Asians
- (2015) Daisuke Yabe et al. Current Diabetes Reports
- A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the Long-Term ASP1941 Safety Evaluation in Patients with Type 2 Dia
- (2015) A. Kashiwagi et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of sodium–glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2 years
- (2015) Xiang-Yang Liu et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Type 2 Diabetes, SGLT2 Inhibitors, and Glucose Secretion
- (2015) Andrew T. Hattersley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus
- (2015) Yutaka Seino et al. Journal of Diabetes Investigation
- Empagliflozin Monotherapy in Japanese Patients with Type 2 Diabetes Mellitus: a Randomized, 12-Week, Double-Blind, Placebo-Controlled, Phase II Trial
- (2014) Takashi Kadowaki et al. ADVANCES IN THERAPY
- Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study
- (2014) Kohei Kaku et al. Cardiovascular Diabetology
- Dapagliflozin as Monotherapy in Drug-Naive Asian Patients With Type 2 Diabetes Mellitus: A Randomized, Blinded, Prospective Phase III Study
- (2014) Linong Ji et al. CLINICAL THERAPEUTICS
- Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study
- (2014) Yutaka Seino et al. CURRENT MEDICAL RESEARCH AND OPINION
- Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study
- (2014) Yutaka Seino et al. CURRENT MEDICAL RESEARCH AND OPINION
- Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study
- (2014) Yutaka Seino et al. CURRENT MEDICAL RESEARCH AND OPINION
- Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study
- (2014) A. Kashiwagi et al. DIABETES OBESITY & METABOLISM
- Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea
- (2014) L. Ji et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise
- (2014) K. Kaku et al. DIABETES OBESITY & METABOLISM
- OP7 EFFICACY, SAFETY, AND TOLERABILITY OF IPRAGLIFLOZIN IN ASIAN TYPE 2 DIABETIC PATIENTS WITH INADEQUATE GLYCEMIC CONTROL WITH METFORMIN. RESULTS OF A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER TRIAL
- (2014) L.-M. Chuang et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study
- (2014) Nobuya Inagaki et al. EXPERT OPINION ON PHARMACOTHERAPY
- Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes
- (2013) Despoina Vasilakou et al. ANNALS OF INTERNAL MEDICINE
- Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States
- (2013) Ronald C.W. Ma et al. Annals of the New York Academy of Sciences
- Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study
- (2013) N. Inagaki et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials
- (2013) M. Monami et al. DIABETES OBESITY & METABOLISM
- Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society
- (2013) Elizabeth R. Seaquist et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus
- (2013) Atsunori Kashiwagi et al. Journal of Diabetes Investigation
- Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
- (2013) Michael Roden et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial
- (2012) K. Kaku et al. DIABETES OBESITY & METABOLISM
- Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs
- (2011) C. Ll. Morgan et al. DIABETES OBESITY & METABOLISM
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search